BC Week In Review | Jan 5, 2015
Clinical News

THR-18: Additional Phase IIa data

A double-blind, placebo-controlled, Ukrainian Phase IIa trial in 30 patients with acute ischemic stroke showed that THR-18 in combination with tissue plasminogen activator (tPA) met the primary safety endpoint. Specifically, no patients receiving THR-18 plus...
BC Week In Review | Mar 10, 2014
Clinical News

THR-18: Interim Phase IIa data

Interim data from the first cohort of patients with acute ischemic stroke in a double-blind, placebo-controlled, Ukrainian Phase IIa trial showed that a single dose of 0.18 mg/kg THR-18 in combination with tissue plasminogen activator...
BC Week In Review | Oct 21, 2013
Clinical News

THR-18: Phase IIa start

On Oct. 22, D-Pharm said it will begin a double-blind, placebo-controlled, Ukrainian Phase IIa trial to evaluate 3 single ascending-doses of THR-18 in combination with tissue plasminogen activator (tPA) in about 30 patients with acute...
BC Week In Review | May 28, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In February, D-Pharm said it was in negotiations...
BioCentury | May 28, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Furiex Pharmaceuticals Inc. (NASDAQ:FURX) gained $3.34 (21%) to $19.10 last week after EMA accepted for review an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for alogliptin to treat Type II diabetes. The acceptance...
BC Extra | May 25, 2012
Company News

D-Pharm, Thrombotech to merge

D-Pharm Ltd. (Tel Aviv:DPRM) will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In...
BC Week In Review | Mar 5, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after discontinuing development of its own stroke therapy in January due to lack of efficacy. On Jan. 24, D-Pharm plummeted...
BioCentury | Mar 5, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) jumped $1.63 (71%) to $3.94 on Tuesday, while partner pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.27 (13%) to $2.42, after the U.K. and six other EU member states reached an...
BC Extra | Feb 28, 2012
Company News

D-Pharm seeking Thrombotech acquisition after Phase III halt

D-Pharm Ltd. (Tel Aviv:DPRM) said it is in negotiations to acquire stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal after discontinuing development of its own stroke therapy last month due to lack...
BC Week In Review | Jan 23, 2012
Financial News

Thrombotech completes venture financing

Thrombotech Ltd. , Ness Ziona, Israel   Business: Cardiovascular   Date completed: 1/18/12   Type: Venture financing   Raised: $1.4 million   Investors: Clal Biotechnology Industries; Ofer Hi-Tech Group; Hadasit  ...
Items per page:
1 - 10 of 12
BC Week In Review | Jan 5, 2015
Clinical News

THR-18: Additional Phase IIa data

A double-blind, placebo-controlled, Ukrainian Phase IIa trial in 30 patients with acute ischemic stroke showed that THR-18 in combination with tissue plasminogen activator (tPA) met the primary safety endpoint. Specifically, no patients receiving THR-18 plus...
BC Week In Review | Mar 10, 2014
Clinical News

THR-18: Interim Phase IIa data

Interim data from the first cohort of patients with acute ischemic stroke in a double-blind, placebo-controlled, Ukrainian Phase IIa trial showed that a single dose of 0.18 mg/kg THR-18 in combination with tissue plasminogen activator...
BC Week In Review | Oct 21, 2013
Clinical News

THR-18: Phase IIa start

On Oct. 22, D-Pharm said it will begin a double-blind, placebo-controlled, Ukrainian Phase IIa trial to evaluate 3 single ascending-doses of THR-18 in combination with tissue plasminogen activator (tPA) in about 30 patients with acute...
BC Week In Review | May 28, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In February, D-Pharm said it was in negotiations...
BioCentury | May 28, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Furiex Pharmaceuticals Inc. (NASDAQ:FURX) gained $3.34 (21%) to $19.10 last week after EMA accepted for review an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for alogliptin to treat Type II diabetes. The acceptance...
BC Extra | May 25, 2012
Company News

D-Pharm, Thrombotech to merge

D-Pharm Ltd. (Tel Aviv:DPRM) will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In...
BC Week In Review | Mar 5, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after discontinuing development of its own stroke therapy in January due to lack of efficacy. On Jan. 24, D-Pharm plummeted...
BioCentury | Mar 5, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) jumped $1.63 (71%) to $3.94 on Tuesday, while partner pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.27 (13%) to $2.42, after the U.K. and six other EU member states reached an...
BC Extra | Feb 28, 2012
Company News

D-Pharm seeking Thrombotech acquisition after Phase III halt

D-Pharm Ltd. (Tel Aviv:DPRM) said it is in negotiations to acquire stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal after discontinuing development of its own stroke therapy last month due to lack...
BC Week In Review | Jan 23, 2012
Financial News

Thrombotech completes venture financing

Thrombotech Ltd. , Ness Ziona, Israel   Business: Cardiovascular   Date completed: 1/18/12   Type: Venture financing   Raised: $1.4 million   Investors: Clal Biotechnology Industries; Ofer Hi-Tech Group; Hadasit  ...
Items per page:
1 - 10 of 12